胆汁酸与脂肪酸可作为局部治疗淋病的候选速效杀菌剂
针对淋球菌耐药性上升及口咽部感染治疗困难,本研究检验胆汁酸和短/中链脂肪酸的快速杀菌活性。结果显示脱氧胆酸(DCA)和鹅去氧胆酸(CDCA)在1分钟内使淋球菌存活率下降超过10万倍,且对多种耐药临床分离株有效,提示其可作为局部治疗候选药物。
要点
- DCA和CDCA在1分钟内使淋球菌存活率下降超过10万倍
- 甲酸和己酸也具快速杀菌活性,四种分子对耐药菌株有效
- DCA和CDCA已获批用于非感染适应症,局部耐受性良好
核心结论
- DCA和CDCA是有吸引力的抗淋球菌候选药物,值得进一步开发。
研究设计与样本
- 体外研究,检测胆汁酸和短/中链脂肪酸对淋球菌的快速杀菌活性。
主要发现
- DCA和CDCA在1分钟内使淋球菌存活率下降超过10万倍,其他胆汁酸无此作用。
- 甲酸和己酸也具快速杀菌活性,四种分子对系统发育多样的淋球菌株有效。
- 有效菌株包括外排泵上调及对常用抗菌药物类别有耐药等位基因的临床分离株。
- DCA和CDCA对培养上皮细胞耐受良好。
关键数值与推荐
- DCA和CDCA在1分钟内使淋球菌存活率下降超过10万倍。
- 四种分子对包括耐药临床分离株在内的多样菌株有效。
临床怎么用
- DCA和CDCA可考虑作为局部治疗淋病(尤其口咽部感染)的候选药物进一步开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Novel therapeutic strategies are urgently needed for Neisseria gonorrhoeae, given its increasing antimicrobial resistance. Treatment of oropharyngeal N. gonorrhoeae infections has proven particularly challenging, with most reported treatment failures of the first-line drug ceftriaxone occurring at this site and lower cure rates in recent trials of new antibiotics reported for oropharyngeal infections compared with other sites of infection. However, the accessibility of the oropharynx to topical therapeutics provides an opportunity for intervention. Local delivery of a therapeutic at a high concentration would enable the use of non-traditional antimicrobial candidates, including biological molecules that exploit underlying chemical sensitivities of N. gonorrhoeae but lack the potency or pharmacokinetic profiles required for effective systemic administration. METHODS: Two classes of molecules that are thought to limit gonococcal viability in vivo, bile acids and short- and medium-chain fatty acids, were examined for rapid bactericidal activity. RESULTS: The bile acids deoxycholic acid (DCA) and chenodeoxycholic acid (CDCA), but not other bile acid species, exerted extremely rapid bactericidal properties against N. gonorrhoeae, reducing viability more than 100 000-fold after 1 min. The short-chain fatty acids formic acid and hexanoic acid shared this rapid bactericidal activity. All four molecules are effective against a phylogenetically diverse panel of N. gonorrhoeae strains, including clinical isolates with upregulated efflux pumps and resistance alleles to the most widely used classes of existing antimicrobials. DCA and CDCA are both approved therapeutics for non-infectious indications and are well-tolerated by cultured epithelial cells. CONCLUSIONS: DCA and CDCA are attractive candidates for further development as anti-gonococcal agents.
引用
- Palace SG, Fryling KE, Li Y, et al. Identification of bile acid and fatty acid species as candidate rapidly bactericidal agents for topical treatment of gonorrhoea. J Antimicrob Chemother. 2021. PMID: 34245280. doi:10.1093/jac/dkab217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。